A Phase I/IIa Study to Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment in Patients With Solid Tumor

Trial Profile

A Phase I/IIa Study to Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment in Patients With Solid Tumor

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs MG-D-1509 (Primary) ; MG-005; Sorafenib
  • Indications Liver cancer; Lung cancer; Renal cancer; Solid tumours
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Metagone Biotech
  • Most Recent Events

    • 20 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 Jun 2018.
    • 30 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top